GE HealthCare Technologies Inc.
GEHCGE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals.
Drugs in Pipeline
18
Phase 3 Programs
10
Upcoming Catalysts
2
Next Catalyst
Jul 29, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
DatSCAN
Lewy Body Dementia
DaTSCAN™ Ioflupane (123I) Injection
Parkinsonian Syndrome
SPECT
Parkinson Disease
Sonazoid™
Liver Lesions
123I-mIBG (meta-iodobenzylguanidine)
Heart Failure, Congestive
Gadodiamide Injection
Aorto-iliac Stenosis
[18F] Flutemetamol
Normal Pressure Hydrocephalus
Flutemetamol (18F) Injection
Mild Cognitive Impairment
[18F]Flutemetamol
Alzheimer's Disease
PET MPI
Coronary Artery Disease (CAD)
GE-145 (AN113111) Injection
Healthy
GE-145
Chronic Renal Insufficiency
Regadenoson
Myocardial Ischemia
Ioforminol 160 mgI/mL
Healthy
Flurpiridaz (18F) Injection
Coronary Artery Disease (CAD)
Fluciclatide Injection
Solid Tumors
Fluciclatide Injection - (AH111585 (F18))
High-grade Glioma
AH110690 (18F) Injection
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DatSCAN | Phase 3 | Lewy Body Dementia | - | - |
DaTSCAN™ Ioflupane (123I) Injection | Phase 3 | Parkinsonian Syndrome | - | - |
SPECT | Phase 3 | Parkinson Disease | - | - |
Sonazoid™ | Phase 3 | Liver Lesions | - | - |
123I-mIBG (meta-iodobenzylguanidine) | Phase 3 | Heart Failure, Congestive | - | - |
Gadodiamide Injection | Phase 3 | Aorto-iliac Stenosis | - | - |
[18F] Flutemetamol | Phase 3 | Normal Pressure Hydrocephalus | - | - |
Flutemetamol (18F) Injection | Phase 3 | Mild Cognitive Impairment | - | - |
[18F]Flutemetamol | Phase 3 | Alzheimer's Disease | - | - |
PET MPI | Phase 3 | Coronary Artery Disease (CAD) | - | - |
GE-145 (AN113111) Injection | Phase 2 | Healthy | - | - |
GE-145 | Phase 2 | Chronic Renal Insufficiency | - | - |
Regadenoson | Phase 2 | Myocardial Ischemia | - | - |
Ioforminol 160 mgI/mL | Phase 2 | Healthy | - | - |
Flurpiridaz (18F) Injection | Phase 2 | Coronary Artery Disease (CAD) | - | - |
Fluciclatide Injection | Phase 2 | Solid Tumors | - | - |
Fluciclatide Injection - (AH111585 (F18)) | Phase 2 | High-grade Glioma | - | - |
AH110690 (18F) Injection | Phase 2 | Alzheimer's Disease | - | - |